#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Stevens-Johnson syndrome Osteosarcoma Cutaneous T-cell lymphoma stage II Neuromyelitis optica spectrum disorder Lymphatic malformation Oesophageal carcinoma Primary myelofibrosis Autologous haematopoietic stem cell transplant Hyperinsulinaemic hypoglycaemia Lymphangioma Craniopharyngioma Hereditary optic atrophy Drug eruption Lennox-Gastaut syndrome Leiomyosarcoma recurrent More trials…

    Learn about Rare Diseases

    Richter’s syndrome – Treatment MELAS syndrome – Trials in Disease Idiopathic inflammatory myopathy – Life with Disease Chondrosarcoma Mastocytosis – Basic Information Hairy cell leukaemia – Trials in Disease Gastrointestinal stromal tumour – Diagnostics Glycogen storage disease type II – Life with Disease Basal cell naevus syndrome – Diagnostics Stevens-Johnson syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Caba-201 Stiripentol Ammonium Chloride Dacarbazine Citrate Certolizumab Pegol Ngm707 Tolu Balsam Umeclidinium EGANELISIB Perflubutane Infigratinib Kbp-336 Melphalan Hydrochloride Messenger Rna Encoding Cas9 DESMOPRESSIN ACETATE Clavulanic Acid VERTEPORFIN Human Normal Immunoglobulin Semaglutide Ivacaftor More therapies…

    Learn about Your Condition

    Tardive dyskinesia Vascular graft thrombosis Gastric cancer recurrent Peripheral artery stenosis Adrenogenital syndrome Dupuytren's contracture Childhood asthma Endolymphatic hydrops Rhabdomyosarcoma Abdominal pain Diminished ovarian reserve Choroid melanoma Systemic lupus erythematosus Infective uveitis Rheumatic disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Post-acute COVID-19 syndrome

  • Study of FLUDEOXYGLUCOSE (18F) PET Imaging of Brain Metabolism in Patients with Persistent Post‑COVID Syndrome

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Post-acute COVID-19 syndrome
    Investigated Drugs:
    • Fludeoxyglucose (18F)
    The Netherlands

  • Total-Body PET with [18F]Flutemetamol in Patients with Post-COVID Syndrome (Long COVID)

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Post-acute COVID-19 syndrome
    Investigated Drugs:
    • Flutemetamol (18F)
    The Netherlands

  • Randomized trial of bupropion hydrochloride for fatigue in patients with long COVID (post‑COVID syndrome)

    Recruiting

    2 1 1
    Investigated Diseases:
    • Post-acute COVID-19 syndrome
    Investigated Drugs:
    • Bupropion Hydrochloride
    Germany

  • A Study of Sonlicromanol for Reducing Fatigue in Patients with Long COVID

    Recruiting

    2 1
    Investigated Drugs:
    • SONLICROMANOL HYDROCHLORIDE
    The Netherlands

  • A Study of Fluvoxamine for Reducing Fatigue in Patients with Post-COVID Condition

    Recruiting

    3 1 1
    Investigated Diseases:
    • Post-acute COVID-19 syndrome
    The Netherlands

  • Study on [68Ga]FAPI-46 to Detect Lung Fibroblast Activity in COVID-19 Patients with Long-Term Symptoms

    Recruiting

    3 1 1
    Investigated Diseases:
    • Post-acute COVID-19 syndrome
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    The Netherlands
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!